TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35649301

Group type: EXPERIMENTAL
Intervention: Trial intervention (not specified in detail)
Number of subjects: 89
Study: 33127287

Group type: EXPERIMENTAL
Intervention: Rotem
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Multiplate
Number of subjects: 59

Group type: COMPARATOR
Intervention: Cyanotic group
Number of subjects: 59

Group type: COMPARATOR
Intervention: Acyanotic group
Number of subjects: 59
Study: 32780844

Group type: EXPERIMENTAL
Intervention: Physical activity group (Fitbit intervention)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard care (education-only group)
Number of subjects: 23
Study: 33789963

Group type: EXPERIMENTAL
Intervention: TDF therapy during the third trimester of pregnancy
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (no treatment during the third trimester)
Number of subjects: 176
Study: 35777562

Group type: COMPARATOR
Intervention: Air filtration intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study: 32869399

Group type: EXPERIMENTAL
Intervention: Heated milk (HM)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Unheated milk (UM)
Number of subjects: 33
Study: 35247098

Group type: EXPERIMENTAL
Intervention: Wheat aleurone (27 g/day)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Cellulose (placebo treatment)
Number of subjects: 67
Study: 32045409

Group type: EXPERIMENTAL
Intervention: SEHER intervention delivered by a lay counsellor (SEHER Mitra [SM])
Number of subjects: 15232

Group type: COMPARATOR
Intervention: Teacher as SEHER Mitra [TSM] intervention
Number of subjects: 15232

Group type: COMPARATOR
Intervention: Control group (Adolescence Education Program [AEP] alone)
Number of subjects: 15232
Study: 35180222

Group type: EXPERIMENTAL
Intervention: Strong warnings with click requirement
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Weak warnings with click requirement
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Strong warnings without click requirement
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Weak warnings without click requirement
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Control group (no warning)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Commonly used TOS warning
Number of subjects: 1500
Study: 34182806

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 28
Study: 32718724

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of Dobutamine and Phenylephrine
Number of subjects: 10
Study: 33587110

Group type: EXPERIMENTAL
Intervention: Flortaucipir PET scan with advanced AD pattern
Number of subjects: 364

Group type: COMPARATOR
Intervention: Flortaucipir PET scan with nonadvanced AD pattern
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Flortaucipir PET scan (advanced AD pattern)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Flortaucipir PET scan (nonadvanced AD pattern)
Number of subjects: 364
Study: 33625468

Group type: EXPERIMENTAL
Intervention: Continuous electrocardiographic (cECG) monitoring with standard care.
Number of subjects: 856

Group type: COMPARATOR
Intervention: Standard care (routine clinical follow-up plus pulse check and heart auscultation).
Number of subjects: 856

Group type: EXPERIMENTAL
Intervention: Home blood pressure (BP) monitor with oscillometric AF screening capability.
Number of subjects: 856
Study: 32275670

Group type: EXPERIMENTAL
Intervention: Unilateral radiation therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Bilateral radiation therapy
Number of subjects: 62
Study: 35286236

Group type: EXPERIMENTAL
Intervention: Guilt Focused Intervention (GFI)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cognitive Behavioral Intervention (CBI)
Number of subjects: 42
Study: 32840598

Group type: EXPERIMENTAL
Intervention: Genotype-guided therapy (ticagrelor for LOF carriers)
Number of subjects: 5302

Group type: COMPARATOR
Intervention: Conventional therapy (clopidogrel)
Number of subjects: 5302

Group type: EXPERIMENTAL
Intervention: Genotype-guided therapy (all randomized patients)
Number of subjects: 5302

Group type: COMPARATOR
Intervention: Conventional therapy (all randomized patients)
Number of subjects: 5302

Group type: EXPERIMENTAL
Intervention: Genotype-guided therapy (major or minor bleeding)
Number of subjects: 5302

Group type: COMPARATOR
Intervention: Conventional therapy (major or minor bleeding)
Number of subjects: 5302
Study: 35427357

Group type: EXPERIMENTAL
Intervention: Lifestyle Africa (intervention)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 494
Study: 34192907

Group type: EXPERIMENTAL
Intervention: Smartphone-based care platform (treatment group)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 365
Study: 32818328

Group type: EXPERIMENTAL
Intervention: Low-energy femtosecond laser pretreatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional phacoemulsification
Number of subjects: 40
Study: 35024497

Group type: EXPERIMENTAL
Intervention: Blue-blocking glasses
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control glasses with partial blue-blocking effect
Number of subjects: 30
Study: 34729065

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 80
Study: 35654467

Group type: EXPERIMENTAL
Intervention: Hypotension Prediction Index (HPI) based treatment protocol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard haemodynamic parameters (Control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: HemoSphere platform parameters (including dynamic arterial elastance, dP/dtmax, and HPI)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy technology for tissue oxygen saturation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Biomarkers of acute kidney stress (cTIMP2 and IGFBP7)
Number of subjects: 80
Study: 33875738

Group type: EXPERIMENTAL
Intervention: Hemostatic agent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bipolar coagulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemostatic agent (in endometriosis patients)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bipolar coagulation (in endometriosis patients)
Number of subjects: 0
Study: 33095509

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1.25 mg of albuterol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2.5 mg of albuterol
Number of subjects: 24
Study: 35364589

Group type: EXPERIMENTAL
Intervention: Clazosentan (10 mg/hr)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 33503629

Group type: EXPERIMENTAL
Intervention: Home-based individually tailored exercise program
Number of subjects: 118

Group type: COMPARATOR
Intervention: Unspecified flexibility training (placebo control)
Number of subjects: 118
Study: 33064137

Group type: EXPERIMENTAL
Intervention: Social risk screening with questions about interest in receiving assistance
Number of subjects: 1021
Study: 35434578

Group type: EXPERIMENTAL
Intervention: 25 µg RBD vaccine
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: 50 µg RBD vaccine
Number of subjects: 792

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: 25 µg RBD vaccine (long schedule)
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: 50 µg RBD vaccine (long schedule)
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: 25 µg RBD vaccine (phase 2)
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: 50 µg RBD vaccine (phase 2)
Number of subjects: 792

Group type: COMPARATOR
Intervention: Placebo (phase 2)
Number of subjects: 792
Study: 33342530

Group type: EXPERIMENTAL
Intervention: Additional monthly SNAP benefits ranging from $1 to $122
Number of subjects: 2202
Study: 35074044

Group type: EXPERIMENTAL
Intervention: psy-PAD (psychodynamically oriented short-term therapy program, eight sessions)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Optimized standard care (control condition)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: psy-PAD
Number of subjects: 143
Study: 33355302

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily
Number of subjects: 2605

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2605
Study: 35202418

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (n = 52)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo (n = 50)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups (Vitamin D supplementation and Placebo)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 33611503

Group type: EXPERIMENTAL
Intervention: PNE plus cognition‐targeted exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neck/back school plus general exercises
Number of subjects: 0
Study: 35779558

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once daily for 14 days
Number of subjects: 472

Group type: COMPARATOR
Intervention: Standard of care (no thromboprophylaxis)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 472

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 472
Study: 34432106

Group type: EXPERIMENTAL
Intervention: on!® nicotine pouches (NPs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Own brand cigarettes (OBCs)
Number of subjects: 0
Study: 32228776

Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Number of subjects: 29
Study: 35481583

Group type: EXPERIMENTAL
Intervention: Tailored physiotherapeutic intervention (three personalized 1-hour sessions with a physiotherapist)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Tailored physiotherapeutic intervention
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 69
Study: 32086657

Group type: EXPERIMENTAL
Intervention: Mothers and Babies (MB) intervention led by paraprofessionals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mothers and Babies (MB) intervention led by mental health professionals
Number of subjects: 0
Study: 34424387

Group type: EXPERIMENTAL
Intervention: Anterior antiglide plate with additional anteroposterior cannulated headless compression screws (group antiGP + HCS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Posterolateral distal humerus locking plate with lateral extension (group PLP)
Number of subjects: 14
Study: 34759112

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid-enriched milk beverage (297 mg docosahexaenoic acid and 137 mg eicosapentaenoic acid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid-enriched milk beverage
Number of subjects: 0
Study: 32708893

Group type: EXPERIMENTAL
Intervention: PE‐5 (75 g glucose ingested 5 min after exercise)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PE‐30 (75 g glucose ingested 30 min after exercise)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (Con - 75 g glucose without exercise)
Number of subjects: 8
Study: 35689188

Group type: EXPERIMENTAL
Intervention: Impulsive Lifestyle Counselling (ILC)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 165
Study: 33652128

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stretching and toning exercises (Control)
Number of subjects: 0
Study: 35871234

Group type: EXPERIMENTAL
Intervention: Adriamycin plus ifosfamide (AI)
Number of subjects: 143

Group type: COMPARATOR
Intervention: gemcitabine plus docetaxel (GD)
Number of subjects: 143
Study: 34162374

Group type: EXPERIMENTAL
Intervention: Sequential MV (n = 24)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional MV (n = 20)
Number of subjects: 44
Study: 32543290

Group type: EXPERIMENTAL
Intervention: IVR combined with exercise (Exercise+IVR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Exercise training (EG)
Number of subjects: 20
Study: 35767837

Group type: EXPERIMENTAL
Intervention: Neuman Systems Model (NSM) approach
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62
Study: 33454124

Group type: EXPERIMENTAL
Intervention: Henagliflozin (2.5-200 mg single ascending dose)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Henagliflozin (1.25-100 mg multiple ascending dose for 10 days)
Number of subjects: 128
Study: 35964133

Group type: EXPERIMENTAL
Intervention: Minimal Contact CBT (MC-CBT)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Education comparator (EDU)
Number of subjects: 240
Study: 34264520

Group type: EXPERIMENTAL
Intervention: PRIME‐EHR
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard EHR
Number of subjects: 120
Study: 32894073

Group type: EXPERIMENTAL
Intervention: First trimester 2D and 3D VR ultrasound examination
Number of subjects: 2800

Group type: COMPARATOR
Intervention: Care as usual: second trimester 2D advanced ultrasound examination
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: First trimester 3D VR ultrasound
Number of subjects: 2800
Study: 35287254

Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy dose >54 Gy
Number of subjects: 225

Group type: COMPARATOR
Intervention: Thoracic radiotherapy dose ≤54 Gy
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy dose >54 Gy in patients with underlying lung disease
Number of subjects: 225
Study: 33475251

Group type: EXPERIMENTAL
Intervention: JNJ‐64565111 5.0 mg
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: JNJ‐64565111 7.4 mg
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: JNJ‐64565111 10.0 mg
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: JNJ‐64565111 (all doses)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: JNJ‐64565111 5.0 mg and 7.4 mg
Number of subjects: 195
Study: 32385134

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 83

Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 83
Study: 35782634

Group type: EXPERIMENTAL
Intervention: Animal-Assisted Therapy (AAT) - 8 sessions
Number of subjects: 33
Study: 33389377

Group type: EXPERIMENTAL
Intervention: Nurse-led mobile phone voice call reminder
Number of subjects: 468

Group type: COMPARATOR
Intervention: Voice call with health promotion message (Control)
Number of subjects: 468
Study: 35482235

Group type: EXPERIMENTAL
Intervention: Hypercapnic hyperoxia (7% CO2, 50% O2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hypercapnic hypoxia (7% CO2, 10% O2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isocapnic hypoxia (10% O2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isocapnic hyperoxia (peripheral chemoreflex inhibition)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hypocapnic hyperoxia (central and peripheral chemoreflex inhibition)
Number of subjects: 20
Study: 34205936

Group type: EXPERIMENTAL
Intervention: Green-colored glasses
Number of subjects: 24

Group type: COMPARATOR
Intervention: Clear glasses
Number of subjects: 24
Study: 33026638

Group type: EXPERIMENTAL
Intervention: Short-form PPoD questionnaire (11 items)
Number of subjects: 803
Study: 36163263

Group type: EXPERIMENTAL
Intervention: Cryoprecipitate (cryo) transfusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (Fg-C; Riastap) transfusion
Number of subjects: 0
Study: 33372103

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg two times per day and lactulose 25 mL two times per day
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo 550 mg two times per day and lactulose 25 mL two times per day
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Rifaximin and lactulose
Number of subjects: 238
Study: 35820991

Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Psychoeducation (Psy-Ed)
Number of subjects: 460
Study: 34957801

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) group with individualized exercise-based training at moderate intensity for 4 weeks after PM implantation.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Non-CR group (control) with no cardiac rehabilitation.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups (CR and non-CR)
Number of subjects: 27
Study: 34922857

Group type: EXPERIMENTAL
Intervention: Bedsharing
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Maternal perception of an infant sleep problem
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Maternal depressive symptoms
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Bedsharing prevalence
Number of subjects: 428
Study: 32966573

Group type: EXPERIMENTAL
Intervention: TDENV-PIV followed by TDENV-LAV
Number of subjects: 80

Group type: COMPARATOR
Intervention: TDENV-LAV followed by TDENV-PIV
Number of subjects: 80
Study: 32957009

Group type: EXPERIMENTAL
Intervention: Lunch
Number of subjects: 99

Group type: COMPARATOR
Intervention: Lunch-omission
Number of subjects: 99
Study: 35555247

Group type: EXPERIMENTAL
Intervention: TEMP (26°C)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: WARM (31°C)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: HOT (36°C)
Number of subjects: 15
Study: 33858527

Group type: EXPERIMENTAL
Intervention: Integrative approach (psychoeducation, mindfulness training, functional remediation)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Integrative approach
Number of subjects: 65

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 65
Study: 34265047

Group type: EXPERIMENTAL
Intervention: Belumosudil 200 mg daily
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Belumosudil 200 mg twice daily
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Belumosudil (both dosages)
Number of subjects: 132
Study: 32787892

Group type: EXPERIMENTAL
Intervention: Iodophor solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: Chlorhexidine solution
Number of subjects: 30
Study: 37312098

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (3 sessions/week, 40 min/session for 12 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 30

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 30
Study: 32475838

Group type: EXPERIMENTAL
Intervention: Oral antidiabetic agents (OAD) including metformin, sitagliptin, or pioglitazone
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 34865232

Group type: EXPERIMENTAL
Intervention: Psycho-educational, web-based resource to reduce negative insulin appraisals
Number of subjects: 35

Group type: COMPARATOR
Intervention: Existing online information about insulin
Number of subjects: 35
Study: 32092047

Group type: EXPERIMENTAL
Intervention: PCV-VG
Number of subjects: 60
Study: 33610731

Group type: EXPERIMENTAL
Intervention: EPM-delivered KRAS siRNA (siKRAS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EPM-mediated introduction of wild-type (WT) p53 pDNA (pcDNA-p53)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exogenous WT p53
Number of subjects: 0
Study: 33218563

Group type: EXPERIMENTAL
Intervention: Iontophoresis with aluminum chloride hexahydrate (ACH) gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tap water iontophoresis
Number of subjects: 20
Study: 34757812

Group type: EXPERIMENTAL
Intervention: AAP + SOC
Number of subjects: 515

Group type: COMPARATOR
Intervention: docetaxel + SOC
Number of subjects: 515
Study: 34114980

Group type: EXPERIMENTAL
Intervention: Acupoint injection combined with pelvic floor rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pelvic floor rehabilitation alone
Number of subjects: 0
Study: 35331823

Group type: EXPERIMENTAL
Intervention: Stepped care trauma‐focused cognitive behavioral therapy (SC‐TF‐CBT)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Trauma-focused cognitive behavioral therapy (TF-CBT)
Number of subjects: 183
Study: 33199421

Group type: EXPERIMENTAL
Intervention: Laparoscopic bowel resection combined with infliximab treatment
Number of subjects: 106

Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 106
Study: 35789217

Group type: EXPERIMENTAL
Intervention: Glycerol throat spray containing cold-adapted cod trypsin (GCTS), administered six times daily at first sign of a common cold
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (nontreated)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycerol throat spray containing cold-adapted cod trypsin (GCTS)
Number of subjects: 0
Study: 34022840

Group type: EXPERIMENTAL
Intervention: Digital alcohol moderation intervention + Treatment as Usual (TAU)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 156
Study: 32771299

Group type: EXPERIMENTAL
Intervention: Stress balls during treatment (Group 1)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Listening to music during treatment (Group 2)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard of care only (Group 3, Control)
Number of subjects: 55
Study: 35022886

Group type: EXPERIMENTAL
Intervention: Interdisciplinary collaborative hospice care (ICHC)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Life-sustaining treatment (LST)
Number of subjects: 166
Study: 34774040

Group type: EXPERIMENTAL
Intervention: National Exercise Referral Scheme (NERS)
Number of subjects: 50
Study: 32397748

Group type: EXPERIMENTAL
Intervention: Dorsolateral prefrontal cortex a‐tDCS (1.5 mA, 20 minutes, six sessions over two weeks)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Primary motor a‐tDCS (1.5 mA, 20 minutes, six sessions over two weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham a‐tDCS (20 minutes, six sessions over two weeks)
Number of subjects: 39
Study: 35544283

Group type: COMPARATOR
Intervention: MST+tDCSsham
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: MST+tDCS
Number of subjects: 25
Study: 34561419

Group type: EXPERIMENTAL
Intervention: Syngeneic HSCT (Syn)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Autologous HSCT (Auto)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Allogeneic HSCT from HLA-matched sibling donor (MSD)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Allogeneic HSCT from HLA-matched unrelated donor (MUD)
Number of subjects: 26